[Hematopoietic stem cell transplantation ocular complications: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Prise en charge des complications ophtalmologiques de l’allogreffe de cellules souches hématopoïétiques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC).
Allogreffe de cellules souches hématopoïétiques
Eye
Graft-versus-host disease
Hematopoietic stem cell allogeneic transplantation
Oculaire
Ocular
Ophtalmologic
Ophtalmologique
Réaction du greffon contre l’hôte
Œil
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
17
02
2020
revised:
08
04
2020
accepted:
15
04
2020
pubmed:
8
7
2020
medline:
29
12
2020
entrez:
8
7
2020
Statut:
ppublish
Résumé
Allogeneic stem cell transplantation is currently the only curative therapy for hematological disorders. This treatment can lead to complications, of which ophtalmological involvement. We reviewed the literature and established accessible and convenient recommendations for hematologists and ophthalmologists. Ophtalmological follow-up should be done in every patient having had an allogeneic transplantation, by the hematologist questioning and by the ophthalmologist physical exam. Complications due to graft-versus-host disease (GVHD) or not due to GVHD are cited, as well as therapeutic options. Screening and treatment of ophthalmologic complications in allogeneic stem cells transplantation recipients requires a close collaboration between hematologists and ophthalmologists. The management of these patients by caregivers trained in these questions is encouraged.
Identifiants
pubmed: 32631612
pii: S0007-4551(20)30257-5
doi: 10.1016/j.bulcan.2020.04.014
pii:
doi:
Types de publication
Journal Article
Practice Guideline
Langues
fre
Sous-ensembles de citation
IM
Pagination
S116-S121Informations de copyright
Copyright © 2020. Published by Elsevier Masson SAS.